Equities analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to post earnings of ($0.11) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings per share of ($0.22) in the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.
On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.41). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.56) to ($0.39). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02).
Several institutional investors have recently added to or reduced their stakes in VKTX. Janney Montgomery Scott LLC purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $114,000. Strs Ohio purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $120,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $129,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $144,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Viking Therapeutics during the second quarter worth approximately $145,000. Institutional investors and hedge funds own 53.22% of the company’s stock.
Shares of VKTX opened at $18.07 on Thursday. The company has a market capitalization of $1.15 billion, a P/E ratio of -22.87 and a beta of 2.86. Viking Therapeutics has a 52-week low of $1.42 and a 52-week high of $24.00.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Featured Article: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.